Advertisement
Canada markets close in 4 hours 3 minutes
  • S&P/TSX

    21,937.79
    +52.41 (+0.24%)
     
  • S&P 500

    5,101.51
    +53.09 (+1.05%)
     
  • DOW

    38,239.05
    +153.25 (+0.40%)
     
  • CAD/USD

    0.7311
    -0.0012 (-0.17%)
     
  • CRUDE OIL

    83.91
    +0.34 (+0.41%)
     
  • Bitcoin CAD

    86,869.62
    -831.64 (-0.95%)
     
  • CMC Crypto 200

    1,319.67
    -76.87 (-5.50%)
     
  • GOLD FUTURES

    2,348.50
    +6.00 (+0.26%)
     
  • RUSSELL 2000

    1,994.44
    +13.32 (+0.67%)
     
  • 10-Yr Bond

    4.6650
    -0.0410 (-0.87%)
     
  • NASDAQ

    15,928.78
    +317.02 (+2.03%)
     
  • VOLATILITY

    15.39
    +0.02 (+0.13%)
     
  • FTSE

    8,139.83
    +60.97 (+0.75%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6837
    +0.0016 (+0.23%)
     

Adamas to Announce Third Quarter 2020 Financial Results and Host Conference Call on November 5, 2020

EMERYVILLE, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 third quarter financial results on Thursday, November 5, 2020, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

Investor Conference Call and Webcast
The conference call can be accessed by dialing (844) 215-3280 for participants in the U.S. or Canada and (484) 747-6383 for international callers. All callers must provide the following Conference ID: 1578986. The webcast can be accessed live via the investor section of the Adamas website at https://ir.adamaspharma.com/events-presentations and will be available for replay until December 5, 2020.

About Adamas Pharmaceuticals, Inc.
At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.

Contact

Media:
Sarah Mathieson
Vice President, Corporate Communications
510-450-3528
smathieson@adamaspharma.com

Investors:
Peter Vozzo
Managing Director, Westwicke
443-213-0505
peter.vozzo@westwicke.com